BEAM
Price
$25.76
Change
+$0.37 (+1.46%)
Updated
Oct 14, 03:51 PM (EDT)
Capitalization
2.66B
27 days until earnings call
MDXG
Price
$6.43
Change
-$0.08 (-1.23%)
Updated
Oct 14, 12:21 PM (EDT)
Capitalization
963.22M
15 days until earnings call
Interact to see
Advertisement

BEAM vs MDXG

Header iconBEAM vs MDXG Comparison
Open Charts BEAM vs MDXGBanner chart's image
Beam Therapeutics
Price$25.76
Change+$0.37 (+1.46%)
Volume$822
Capitalization2.66B
MiMedx Group
Price$6.43
Change-$0.08 (-1.23%)
Volume$900
Capitalization963.22M
BEAM vs MDXG Comparison Chart in %
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. MDXG commentary
Oct 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and MDXG is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 14, 2025
Stock price -- (BEAM: $25.39 vs. MDXG: $6.51)
Brand notoriety: BEAM and MDXG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 103% vs. MDXG: 87%
Market capitalization -- BEAM: $2.66B vs. MDXG: $963.22M
BEAM [@Biotechnology] is valued at $2.66B. MDXG’s [@Biotechnology] market capitalization is $963.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $104.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileMDXG’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • MDXG’s FA Score: 1 green, 4 red.
According to our system of comparison, BEAM is a better buy in the long-term than MDXG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while MDXG’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 5 bearish.
  • MDXG’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than MDXG.

Price Growth

BEAM (@Biotechnology) experienced а -1.93% price change this week, while MDXG (@Biotechnology) price change was -10.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.19%. For the same industry, the average monthly price growth was +14.60%, and the average quarterly price growth was +79.49%.

Reported Earning Dates

BEAM is expected to report earnings on Nov 10, 2025.

MDXG is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+1.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.66B) has a higher market cap than MDXG($963M). BEAM YTD gains are higher at: 2.379 vs. MDXG (-32.328). MDXG has higher annual earnings (EBITDA): 52.7M vs. BEAM (-414.33M). BEAM has more cash in the bank: 1.15B vs. MDXG (119M). MDXG has less debt than BEAM: MDXG (18.5M) vs BEAM (155M). MDXG has higher revenues than BEAM: MDXG (364M) vs BEAM (60.3M).
BEAMMDXGBEAM / MDXG
Capitalization2.66B963M277%
EBITDA-414.33M52.7M-786%
Gain YTD2.379-32.328-7%
P/E RatioN/A31.00-
Revenue60.3M364M17%
Total Cash1.15B119M966%
Total Debt155M18.5M838%
FUNDAMENTALS RATINGS
MDXG: Fundamental Ratings
MDXG
OUTLOOK RATING
1..100
60
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
98
SMR RATING
1..100
51
PRICE GROWTH RATING
1..100
58
P/E GROWTH RATING
1..100
6
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMMDXG
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
68%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
STITX7.48N/A
N/A
Virtus SGA International Growth I
LSGRX33.45N/A
N/A
Loomis Sayles Growth Y
NDVCX15.58N/A
N/A
MFS New Discovery Value C
SFDYX31.47N/A
N/A
SEI Mid-Cap Y (SIMT)
BUIIX23.73N/A
N/A
Buffalo International Institutional

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-3.53%
CRSP - BEAM
66%
Closely correlated
-6.54%
NTLA - BEAM
63%
Loosely correlated
-3.10%
RXRX - BEAM
62%
Loosely correlated
+3.95%
AXON - BEAM
57%
Loosely correlated
+0.99%
PRME - BEAM
55%
Loosely correlated
-0.53%
More